CINCINELLI, GILBERTO
CINCINELLI, GILBERTO
Dipartimento di Scienze Cliniche e di Comunità
Effectiveness and safety of upadacitinib in juvenile idiopathic arthritis: beyond the polyarticular subset in pediatric and adult patients
2025 S. Costi, L. Ingrao, M.G. Lommano, G. Cincinelli, F. Baldo, A. Marino, R. Caporali, C.B. Chighizola
Expanding the expanded risk score to psoriatic arthritis: any port in a storm
2025 E.G. Favalli, L. Ingrao, G. Trignani, M. Ferrito, G. Cincinelli, R. Caporali
Patient-Derived Explants of Osteoarthritic Synovium as Ex Vivo Model for Preclinical Research
2025 C. D'Oria, G. Cincinelli, R. Bason, F. Pisati, F. Simoncello, I. Scotti, L. Giudice, I. Suardi, P. Ferrua, C. Fossati, P.S. Randelli, R. Caporali, M. Pagani, F. Ingegnoli
Difficult-to-treat psoriatic arthritis: refining the definition using a statistical model in a real-life cohort
2024 E.G. Favalli, G. Biganzoli, G. Cincinelli, M. Ferrito, E. Luconi, M. Manara, M. Biggioggero, P. Boracchi, R. Caporali
Predictors of lack of response to methotrexate in juvenile idiopathic arthritis associated uveitis
2024 C. Mapelli, E. Miserocchi, M. Nassisi, G.B. Beretta, L. Marelli, G. Leone, A. Marino, C. Chighizola, G. Cincinelli, T. Giani, P. Nucci, F. Viola, G. Filocamo, F. Minoia, C. Agostoni, F. Baldo, L. Baselli, S. Costi, F. Di Stasio, M. Gattinara, S. Lanni, A. Petaccia, M. Rossano, F. Vianello, N. Null
The change over time in the prescription pattern of the first targeted drug after failure of conventional therapy in patients with rheumatoid arthritis: a 20-year real-world experience
2024 G. Maioli, G. Cincinelli, M. Biggioggero, R. Caporali, E.G. Favalli
Truth unveiled by time and the marbled definition of D2T-RA: retrospective analysis on the persistence of the difficult-to-treat status among refractory RA patients
2024 G. Cincinelli, G. Maioli, C. Posio, E.G. Favalli, F. Ingegnoli, R. Caporali
Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients
2023 M. Ferrito, G. Cincinelli, M. Manara, R. Di Taranto, E.G. Favalli, R. Caporali
The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events
2023 E.G. Favalli, G. Cincinelli, S. Germinario, R. Di Taranto, F. Orsini, G. Maioli, M. Biggioggero, M. Ferrito, R. Caporali
Tight control in patients with rheumatoid arthritis treated with targeted therapies across the COVID-19 pandemic era
2023 A.F. Luppino, G. Cincinelli, A. Orenti, P. Boracchi, E.G. Favalli, R. Caporali, F. Ingegnoli
Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy
2021 F. Ingegnoli, G. Cincinelli, A.F. Luppino, E.G. Favalli, A. Orenti, P. Boracchi, R. Caporali
Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis
2021 A. Zabotti, O. De Lucia, G. Sakellariou, A. Batticciotto, G. Cincinelli, I. Giovannini, L. Idolazzi, G. Maioli, I. Tinazzi, D. Aletaha, S. De Vita, A. Marchesoni, J. Smolen, A. Iagnocco, D. Mcgonagle, R. Caporali
A case report of monoarthritis in a COVID-19 patient and literature review: Simple actions for complex times
2021 G. Cincinelli, R. Di Taranto, F. Orsini, A. Rindone, A. Murgo, R. Caporali
COVID-19 infection and rheumatoid arthritis: Faraway, so close!
2020 E.G. Favalli, F. Ingegnoli, O. De Lucia, G. Cincinelli, R. Cimaz, R. Caporali